National comprehensive cancer network (NCCN) recommendations for drugs without US food and drug administration (FDA) approval in metastatic breast cancer: A cross-sectional study

被引：0
|
作者：
Etan, Tal [1 ]
Amir, Eitan [2 ]
Tibau, Adriana [3 ]
Yerushalmi, Rinat [4 ]
Moore, Assaf [4 ]
Shepshelovich, Daniel [1 ]
Goldvaser, Hadar [4 ]
机构：
[1] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[2] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
[4] Rabin Med Ctr, Petah Tiqwa, Israel
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS14-13
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer
    Kenji Yamashita
    Masayuki Kaneko
    Mamoru Narukawa
    European Journal of Clinical Pharmacology, 2019, 75 : 1193 - 1200
  • [22] US Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer
    Weinstock, Chana
    Khozin, Sean
    Suzman, Daniel
    Zhang, Lijun
    Tang, Shenghui
    Wahby, Sakar
    Goldberg, Kirsten B.
    Kim, Geoffrey
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2017, 23 (16) : 4534 - 4539
  • [23] Association between Oncologic Drugs Advisory Committee (ODAC) members' financial conflicts of interest (FCOIs) and recommendations for drug approval by the US Food and Drug Administration (FDA)
    Martorell, Ariadna Tibau
    Ocana, Alberto
    Seruga, Bostjan
    Templeton, Arnoud J.
    Barnadas, Agusti
    Amir, Eitan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] Participation of African American Persons in Clinical Trials Supporting US Food and Drug Administration Approval of Cancer Drugs
    Al Hadidi, Samer
    Mims, Martha
    Miller-Chism, Courtney Nicole
    Kamble, Rammurti
    ANNALS OF INTERNAL MEDICINE, 2020, 173 (04) : 320 - +
  • [25] The association between timing in adjuvant chemotherapy administration and overall survival for women with breast cancer within the National Comprehensive Cancer Network (NCCN)
    Vandergrift, J. L.
    Breslin, T. M.
    Niland, J. C.
    Edge, S. B.
    Wolff, A. C.
    Marcom, P. K.
    Rugo, H. S.
    Moy, B.
    Wilson, J. L.
    Ottesen, R. A.
    Weeks, J. C.
    Wong, Y-N
    CANCER RESEARCH, 2012, 72
  • [26] Assessment of psychiatric disorder in patients with metastatic breast cancer: A cross-sectional study
    Basto, R.
    Caramujo, C.
    Ferreira Gomes, I.
    Fraga, T.
    Correia Magalhaes, J.
    Sousa, M. J.
    Monteiro, A. R.
    Pestana Santos, A.
    Carvalho, T.
    Albuquerque, E.
    Sousa, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1097 - S1097
  • [27] Anxiety and Depression in Young Women With Metastatic Breast Cancer: A Cross-Sectional Study
    Park, Eliza M.
    Gelber, Shari
    Rosenberg, Shoshana M.
    Seah, Davinia S. E.
    Schapira, Lidia
    Come, Steven E.
    Partridge, Ann H.
    PSYCHOSOMATICS, 2018, 59 (03) : 251 - 258
  • [28] National Anti-VEGF Utilization for Conditions without US Food and Drug Administration Approval: An IRIS Registry Study
    Zhang, Casey
    Kahan, Elias
    Mittal, Rhiya
    Friedman, Scott
    Lum, Flora
    Parikh, Ravi
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [29] Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
    Austin Lammers
    Ruibin Wang
    Jeremy Cetnar
    Vinay Prasad
    Blood Cancer Journal, 7
  • [30] Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
    Lammers, Austin
    Wang, Ruibin
    Cetnar, Jeremy
    Prasad, Vinay
    BLOOD CANCER JOURNAL, 2017, 7
12345